Analysts Issue Forecasts for WVE Q4 Earnings

Key Points

• HC Wainwright expects WAVE Life Sciences to report a Q4 loss of $0.28 per share and maintains a “Strong Buy” rating; analysts’ consensus projects a full-year loss of $1.12 per share.
• WAVE’s latest quarterly results exceeded expectations, with an adjusted loss of $0.30 per share versus the $0.33 consensus and revenue of $13.16 million versus $4.51 million expected.
• Investor sentiment remains broadly positive, with the stock carrying a “Moderate Buy” consensus rating and a $20.89 average price target, though the company remains unprofitable and dependent on clinical progress, particularly its WVE-006 RNA-editing program.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at HC Wainwright issued their Q4 2027 EPS estimates for WAVE Life Sciences in a report released on Wednesday, October 28th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.12) per share.

Several other equities research analysts have also recently issued reports on the stock. William Blair assumed coverage on shares of WAVE Life Sciences in a research report on Friday, October 16th. They set an "outperform" rating for the company. Citigroup dropped their target price on WAVE Life Sciences from $24.00 to $19.00 and set a "buy" rating on the stock in a report on Friday, July 31st. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a "neutral" rating on the stock. LADENBURG THALM/SH SH started coverage on WAVE Life Sciences in a research note on Thursday, October 1st. They issued a "buy" rating and a $10.00 price target on the stock. Finally, UBS Group started coverage on WAVE Life Sciences in a report on Thursday, October 15th. They set a "buy" rating and a $11.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $20.89.

WAVE Life Sciences Trading Up 5.5%

Shares of WVE opened at $3.64 on Thursday. WAVE Life Sciences has a twelve month low of $3.04 and a twelve month high of $21.73. The firm's fifty day simple moving average is $4.13 and its 200-day simple moving average is $7.60. The firm has a market capitalization of $717.92 million, a price-to-earnings ratio of -3.34 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The company had revenue of $13.16 million during the quarter, compared to analysts' expectations of $4.51 million.

Insider Buying and Selling at WAVE Life Sciences

In other news, Director Adrian Rawcliffe sold 12,700 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heidi Wagner sold 7,000 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the completion of the transaction, the director directly owned 44,930 shares in the company, valued at $270,029.30. This trade represents a 13.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 23,564 shares of company stock valued at $132,476. Company insiders own 24.34% of the company's stock.

Institutional Investors Weigh In On WAVE Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC purchased a new position in WAVE Life Sciences during the 2nd quarter worth approximately $180,000. Squarepoint Ops LLC increased its position in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company's stock worth $14,766,000 after buying an additional 1,029,052 shares during the period. Arizona State Retirement System increased its position in WAVE Life Sciences by 17.1% during the second quarter. Arizona State Retirement System now owns 35,826 shares of the company's stock worth $208,000 after buying an additional 5,228 shares during the period. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences in the second quarter valued at approximately $27,465,000. Finally, AlphaGrep UK Ltd purchased a new stake in WAVE Life Sciences in the second quarter valued at approximately $78,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33–$0.34 analyst consensus. Revenue of $13.16 million also substantially exceeded estimates of approximately $4.51 million, helping ease concerns about the company’s near-term financial performance. Wave Life Sciences Stock Rallies as Q3 Results Ease Loss Fears
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, providing a meaningful future catalyst if the program continues to generate positive data. WAVE Life Sciences Reports Third Quarter Results and Business Update
• Positive Sentiment: Management’s earnings call and business update provided investors with additional detail on the development pipeline and upcoming clinical milestones, supporting optimism around WVE-006 and the company’s broader RNA-editing platform. WAVE Life Sciences Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Oppenheimer reduced its price target to $29 from $32 but maintained an Outperform rating. The lower target is a modest valuation reset, while the unchanged rating indicates the analyst remains constructive on WVE’s long-term prospects. Oppenheimer Adjusts WAVE Life Sciences Price Target
• Negative Sentiment: Despite the earnings beat, WAVE remains unprofitable, reporting a quarterly loss and maintaining substantial cash-burn risk as it funds clinical development. Analysts continue to forecast a full-year loss, leaving the stock highly dependent on future trial progress and financing conditions. WAVE Life Sciences Reports Q3 Loss and Tops Revenue Estimates

About WAVE Life Sciences

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.